Anti-Parkinson Drugs Market Growth Outlook Through 2024-2033

Overview and Scope
Anti-Parkinson drug is a term used to describe the medications that are mostly used to treat Parkinson’s disease. They are not psychiatric medications, so they cannot legally be used to treat mental health issues. However, a doctor or psychiatrist may recommend one of these medications in addition to an antipsychotic to lessen some of the antipsychotic’s negative effects.

Sizing and Forecast
The anti-parkinson drugs market size has grown strongly in recent years. It will grow from <b>$9.73 billion in 2023 to $10.43 billion in 2024 at a compound annual growth rate (CAGR) of 7.2%. </b> The growth in the historic period can be attributed to aging population, increasing disease prevalence, healthcare infrastructure, advancements in research.

The anti-parkinson drugs market size is expected to see strong growth in the next few years. It will grow to <b>$13.36 billion in 2028 at a compound annual growth rate (CAGR) of 6.4%. </b> The growth in the forecast period can be attributed to growing awareness, biotechnological advancements, emerging markets. Major trends in the forecast period include investment in r&d, personalized medicine, disease-modifying therapies, drug repurposing, telemedicine and remote monitoring, biosimilars, research collaborations.

To access more details regarding this report, visit the link:

Segmentation & Regional Insights
The anti-parkinson drugs market covered in this report is segmented –

1) By Drugs Class: Levodopa/Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs
2) By Route of Administration: Oral, Injection, Transdermal
3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies

<b>North America</b> was the largest region in the anti-Parkinson drugs market in 2023. <b>Middle East</b> is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in the anti-parkinson drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

Major Driver Impacting Market Growth
The increasing geriatric population and surging cases of Parkinson’s disease (PD) are projected to drive the demand for the anti-Parkinson drugs market. PD commonly occurs in people over the age of 60 cases of Parkinson’s disease (PD) are projected to drive the demand for the anti-Parkinson drugs market. PD commonly occurs in people over the age of 60. For instance, in October 2022, according to the World Health Organization, a US-based health agency, Globally, 1 in 6 individuals will be 60 or older by 2030, and by 2050, there will be a double amount of individuals in this age group (2.1 billion). Additionally, for instance, in June 2021, according to the UK Parliament’s House of Commons Library, a UK-based information resource, the elderly population in the UK will increase, accounting for 24% of the total population (17.4 million people) by 2043. Therefore, the increasing geriatric population is driving the growth of the anti-parkinson drugs market.

Key Industry Players
Major companies operating in the anti-parkinson drugs market include <b>GlaxoSmithKline plc, Pfizer Inc., Merck Co., Novartis AG, F. Hoffmann-La Roche AG, UCB S.A, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Mylan NV, C.H. Boehringer Sohn AG & Co. KG, Orion Pharma Ltd., ACADIA Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., US WorldMeds LLC, Zydus Lifesciences Limited, Chemical Industrial & Pharmaceutical Laboratories Ltd., Strides Shasun Ltd., Axcan Pharma Inc., Upsher-Smith Laboratories LLC, H. Lundbeck A/S, Vertical Pharmaceuticals LLC, Zambon SPA, M Somerset Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc.</b>

The anti-parkinson drugs market report table of contents includes:

1. Executive Summary
2.Anti-Parkinson Drugs  Market Characteristics
3.Anti-Parkinson Drugs  Market Trends And Strategies
4.Anti-Parkinson Drugs  market analysis
5.Anti-Parkinson Drugs  Market Size And Growth
6.Anti-Parkinson Drugs  Segmentation
7.Anti-Parkinson Drugs  Regional And Country Analysis
27.Anti-Parkinson Drugs  Competitive Landscape And Company Profiles
28.Anti-Parkinson Drugs  Key Mergers And Acquisitions
29.Anti-Parkinson Drugs  Future Outlook and Potential Analysis


  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Merck Co.
  • Novartis AG
  • F. Hoffmann-La Roche AG
  • UCB S.A
  • Teva Pharmaceutical Industries Ltd.

Explore the trending research reports from TBRC:

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: [email protected]

Follow Us On:
Healthcare Blog:
Global Market Model:

Leave a Reply

Your email address will not be published. Required fields are marked *